The researches find that the likelihood of biochemical progression of disease among men who have undergone radiation therapy (RT) intermediate or high-risk prostate cancer (PCa) and are receiving androgen deprivation therapy; according to investigators. Therefore The finding is from a phase 3 study in which Pirkko-Liisa Kellokumpu-Lehtnen, MD, of Tampere University Hospital in Tampere, Finland, and colleagues that included 376 patients who completed RT for intermediate or high-risk PCa. They randomly assigned 188 patients to receive 6 cycles of adjuvant docetaxel without continuous prednisone and 188 to undergo surveillance.
Undergone radiation therapy
Neoadjuvant or adjuvant andogen deprivation therapy was mandatory for all patients. Of the 188 men in the docetaxel arm, 147 (78%) completed all 6 cycles of the drug. Radiotherapy means the use of radiation, usually x-rays; to treat cancer cells. You might have radiotherapy from inside the body; but this is called internal radiotherapy. Or external radiotherapy is from outside of the body. Therefore External radiotherapy can shrink cancer that has spread to other parts of the body or has come back in the prostate after surgery. It can help to reduce pain and other symptoms.
You might have it to treat areas of cancer in the bones. Cancer in the bone can weaken the bone and make it more likely to break (fracture). But radiotherapy can help to strengthen the bone cells. But Radiation therapy; also called X-ray therapy; uses high levels of radiation to kill prostate cancer cells or keep them from growing and dividing, while minimizing damage to healthy cells. Because Radiation can be produced from a machine outside the body (external radiation) ;and directed right at the prostate or by putting materials that produce radiation (radioisotopes) through thin plastic tubes into the cancer-infected area (internal radiation or brachytherapy).
Strengthen the bone cells
Results showed that 58 patients in the docetaxel arm and 57 in the surveillance arm experienced the study’s primary end point of a 2 ng/mL or greater rise in PSA above nadir values; Dr Kellokumpu-Lehtnen’s team reported in European Urology. A Kaplan-Meier analysis revealed no significant difference in biochemical disease-free survival curves. On Cox multivariate analysis; the docetaxel and surveillance groups did not differ significantly ;with regard to PSA progression.The 5-year estimated biochemical progression rates were 31% in the docetaxel arm and 28% in the surveillance arm; the investigators reported.
“In conclusion; based on our current results; there is no evidence that adjuvant docetaxel with ADT after RT would provide a benefit for intermediate or high-risk PCa patients in general clinical practice;” the authors concluded. Therefore Internal radiation therapy places radioactive implants directly into the tumor. But These radioactive sources can be temporary (removed after the proper dose is reached) or permanent.